한글목차

세계 암 바이오마커 시장은 2018년 104억 7,392만 달러로 평가되었으며, 2023년까지 13.50% 이상의 CAGR로 성장할 것으로 예상됩니다.

맞춤형 의료에 대한 수요 증가

맞춤형 의료에 대한 수요 증가는 암 바이오마커 시장의 성장을 가속했습니다. 맞춤의료는 정밀의료 또는 개인맞춤의료라고도 불리며, 환자 개개인의 특성에 맞는 치료와 개입을 목표로 하는 의료 접근법입니다. 맞춤의료는 유전자 구성, 바이오마커 프로파일 및 기타 변수를 포함하여 각 환자의 고유한 속성에 맞게 의료를 맞춤화하려는 시도입니다. 기존의 획일적인 방식에 비해 바이오마커를 이용해 특정 분자 표적을 찾아내어 치료 효과를 높이고 부작용이 적은 표적 의약품을 개발할 수 있습니다. 예를 들어, 2022년 10월, 미국 기반의 과학자, 환자 및 의료 서비스 제공업체를 대표하는 단체인 개인화된 의학 연합(Personalized Medicine Coalition, 환자와 의료 시스템에 혜택을 주는 개인화된 의학의 이해와 보급을 촉진하는 단체)에 따르면, 여러 유형의 암 유전성 희귀질환, 다양한 만성질환 및 감염성 질환 환자들을 위한 75,000개 이상의 유전자 검사 제품과 300개 이상의 개인맞춤형 의약품이 시중에 나와 있는 것으로 추정됩니다. 또한, 개인맞춤형 의료를 옹호하는 미국 개인맞춤의료연합(PMC)에 따르면, 2022년에는 미국 식품의약국(FDA)이 승인하는 신약의 34%를 개인맞춤형 의약품이 차지하게 될 것이며, 지난 8년 동안 모두 개인맞춤형 의약품이 승인 건수의 25% 이상을 차지했다고 합니다. 따라서 맞춤형 의료에 대한 수요 증가는 지난 기간 동안 암 바이오마커 시장의 성장을 뒷받침했습니다.

목차

제1장 주요 요약

• 암 바이오마커 - 시장의 매력과 거시경제 상황

제2장 목차

제3장 표 리스트

제4장 그래프 리스트

제5장 보고서 구성

제6장 시장 특징

• 일반적인 시장의 정의
• 개요
• 암 바이오마커 시장 정의와 세분화
• 바이오마커 유형별 : 시장 세분화
  • 단백질 바이오마커
  • 유전자 바이오마커
  • 기타 암 바이오마커
• 프로파일링 기술별 : 시장 세분화
  • 오믹스 기술
  • 이미징 기술
  • 면역학적 검사
  • 바이오인포매틱스
  • 세포 유전학
• 암 유형별 : 시장 세분화
  • 자궁경부암
  • 유방암
  • 폐암
  • 대장암
  • 전립선암
  • 뇌 및 중추신경계 암
  • 신장암
  • 난소암
  • 위암
  • 기타 암 유형
• 용도별 : 시장 세분화
  • 진단
  • 연구개발
  • 예측
  • 리스크 평가
  • 기타 용도

제7장 주요 시장 동향

제8장 암 바이오마커 시장 : 거시경제 시나리오

• COVID-19의 영향 : 암 바이오마커 시장
• 우크라이나 전쟁의 영향 : 암 바이오마커 시장
• 고인플레이션의 영향 : 암 바이오마커 시장

제9장 세계 시장 규모와 성장

• 시장 규모
• 시장 성장 실적, 2018-2023
  • 시장 성장 촉진요인, 2018-2023
  • 시장 성장 억제요인, 2018-2023
• 시장 성장 예측, 2023-2028, 2033F
  • 시장 성장 촉진요인, 2023-2028
  • 시장 성장 억제요인, 2023-2028

제10장 세계의 암 바이오마커 시장 : 세분화

• 세계의 암 바이오마커 시장 : 바이오마커 유형별, 실적과 예측, 2018-2023, 2028F, 2033F
• 세계의 암 바이오마커 시장 : 프로파일링 기술별, 실적과 예측, 2018-2023, 2028F, 2033F
• 세계의 암 바이오마커 시장 : 용도별, 실적과 예측, 2018-2023, 2028F, 2033F
• 세계의 암 바이오마커 시장 : 암 유형별, 실적과 예측, 2018-2023, 2028F, 2033F

제11장 암 바이오마커 시장 : 지역/국가별 분석

• 세계의 암 바이오마커 시장 : 지역별, 실적과 예측, 2018-2023, 2028F, 2033F
• 세계의 암 바이오마커 시장 : 국가별, 실적과 예측, 2018-2023, 2028F, 2033F

제12장 아시아태평양 시장

제13장 서유럽 시장

제14장 동유럽 시장

제15장 북미 시장

제16장 남미 시장

제17장 중동 시장

제18장 아프리카 시장

제19장 경쟁 구도와 기업 개요

• 기업 개요
• Roche Diagnostics
• Novartis AG
• Illumina Inc.
• Hologic Inc
• Thermo Fisher Scientific Inc.

제20장 경쟁 벤치마킹

제21장 경쟁 대시보드

제22장 주요 인수합병(M&A)

• Novartis Acquired MorphoSys
• Bristol Myers Squibb Acquired Mirati Therapeutics
• Agilent Acquired Avida Biomed
• Quest Diagnostics Acquired Haystack Oncology
• Prenetics Global Acquired ACT Genomics
• Biocare Medical Acquired Empire Genomics
• Agilent Acquired Resolution Bioscience
• Hologic Acquired Biotheranostics

제23장 기회와 전략

• 세계의 암 바이오마커 시장, 2028년 : 새로운 기회를 제공하는 국가
• 세계의 암 바이오마커 시장, 2028년 : 새로운 기회를 제공하는 부문
• 세계의 암 바이오마커 시장, 2028년 : 성장 전략
  • 시장 동향에 근거한 전략
  • 경쟁 전략

제24장 암 바이오마커 시장 : 결론과 제안

• 결론
• 제안
  • 제품
  • 장소
  • 가격
  • 프로모션
  • 사람들

제25장 부록

영문목차

Cancer biomarkers refer to biological molecules found in blood, other body fluids or tissues that are indicative of the presence of cancer in the body. These biomarkers can be proteins, genetic material or other types of molecules that provide critical information about the health status of an individual, especially in the context of cancer.

The cancer biomarker market consists of sales, by entities (organizations, sole traders and partnerships), of diagnostic products and services related to cancer biomarkers that are utilized by healthcare professionals and researchers for a variety of purposes, including the early detection of cancer, monitoring the progression of the disease, evaluating the effectiveness of treatment and predicting prognosis and the likelihood of cancer recurrence. They play a crucial role in personalized medicine, allowing for tailored treatment plans based on the specific biomarkers present in an individual's cancer.

The global cancer biomarker market was valued at $10,473.92 million in 2018 which grew till 2023 at a compound annual growth rate (CAGR) of more than 13.50%.

Increase In Demand For Personalized Medicine

An increase in demand for personalized medicine propelled the growth of the cancer biomarker market. Personalized medicine, also known as precision medicine or individualized medicine, is an approach to medical care that aims to tailor treatments and interventions to the specific characteristics of each patient. Personalized medicine seeks to customize medical care to each patient's unique attributes, including genetic composition, biomarker profile and other variables. When compared to conventional, one-size-fits-all methods, targeted medicines can be developed with greater efficacy and fewer adverse effects thanks to the use of biomarkers in the identification of specific molecular targets for therapy. For instance, in October 2022, according to the Personalized Medicine Coalition, a US-based organization that represents scientists, patients and providers, promoting the understanding and adoption of personalized medicine to benefit patients and the healthcare system) estimated that more than 75,000 genetic testing products and 300 personalized medicines are on the market for people with multiple types of cancers, genetic rare diseases and a range of chronic and infectious diseases. Additionally, in 2022, according to the Personalized Medicine Coalition (PMC), a US-based company that advocates for personalized medicine, personalized medicines will account for 34% of new drug approvals by the US Food and Drug Administration in 2022 and have accounted for at least 25% of approvals in each of the previous eight years. Therefore, the increase in demand for personalized medicine supported the growth of the cancer biomarker market during the historic period.

Focus On AI Solution For Advancing Cancer Diagnostics And Cancer Drugs

Major companies are focused on an AI-driven solution for advancing cancer diagnostics utilizes machine learning algorithms to analyze medical imaging data such as X-rays, MRIs, CT scans and histopathology slides. These algorithms can detect subtle patterns and anomalies indicative of cancerous growths, enabling earlier and more accurate diagnoses. For instance, in September 2023, Ibex Medical Analytics, an Israel-based medical technology manufacturing company and leader in AI-powered cancer diagnostics, announced Galen Breast HER2, an artificial intelligence (AI) solution enhancing accurate and reproducible HER2 scoring in breast cancer patients. Galen Breast HER2 employs AI to detect invasive tumor areas and quantify HER2 expression into standard categories, aiding in patient identification for targeted therapies. The solution offers pathologists a comprehensive AI platform for analyzing H&E and IHC-stained slides, supporting quick and consistent HER2 scoring and enabling full review of breast biopsies with automated quantification of additional biomarkers.

The global cancer biomarker market is highly concentrated, with a few large players dominating in the market. The top ten competitors in the market made up to 51.6% of the total market in 2022

Cancer Biomarker Global Market Opportunities And Strategies To 2033 from The Business Research Company provides the strategists; marketers and senior management with the critical information they need to assess the global cancer biomarker market as it emerges from the COVID-19 shut down.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Understand how the market is being affected by the coronavirus and how it is likely to emerge and grow as the impact of the virus abates.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market research findings.
• Benchmark performance against key competitors.
• Utilize the relationships between key data sets for superior strategizing.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis.

Where is the largest and fastest-growing market for cancer biomarker? How does the market relate to the overall economy; demography and other similar markets? What forces will shape the market going forward? The cancer biomarker market global report from The Business Research Company answers all these questions and many more.

The report covers market characteristics; size and growth; segmentation; regional and country breakdowns; competitive landscape; market shares; trends and strategies for this market. It traces the market's history and forecasts market growth by geography. It places the market within the context of the wider cancer biomarker market; and compares it with other markets.

The report covers the following chapters

• Introduction and Market Characteristics- Brief introduction to the segmentations covered in the market, definitions and explanations about the segment by biomarkers type, by profiling technologies, by cancer type and by application.
• Key Trends- Highlights the major trends shaping the global market. This section also highlights likely future developments in the market.
• Macro-Economic Scenario- The report provides an analysis of the impact of the COVID-19 pandemic, impact of the Russia-Ukraine war and impact of rising inflation on global and regional markets, providing strategic insights for businesses in the cancer biomarker market.
• Global Market Size And Growth- Global historic (2018-2023) and forecast (2023-2028, 2033F) market values and drivers and restraints that support and control the growth of the market in the historic and forecast periods.
• Regional And Country Analysis- Historic (2018-2023) and forecast (2023-2028, 2033F) market values and growth and market share comparison by region and country.
• Market Segmentation- Contains the market values (2018-2023) (2023-2028, 2033F) and analysis for each segment by biomarkers type, by profiling technologies, by cancer type and by application in the market. Historic (2018-2023) and forecast (2023-2028) and (2028-2033) market values and growth and market share comparison by region market.
• Regional Market Size and Growth- Regional market size (2023), historic (2018-2023) and forecast (2023-2028, 2033F) market values and growth and market share comparison of countries within the region. This report includes information on all the regions Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa and major countries within each region.
• Competitive Landscape- Details on the competitive landscape of the market, estimated market shares and company profiles of the leading players.
• Other Major And Innovative Companies- Details on the company profiles of other major and innovative companies in the market.
• Competitive Benchmarking- Briefs on the financials comparison between major players in the market.
• Competitive Dashboard- Briefs on competitive dashboard of major players.
• Key Mergers and Acquisitions- Information on recent mergers and acquisitions in the market is covered in the report. This section gives key financial details of mergers and acquisitions which have shaped the market in recent years.
• Market Opportunities And Strategies- Describes market opportunities and strategies based on findings of the research, with information on growth opportunities across countries, segments and strategies to be followed in those markets.
• Conclusions And Recommendations- This section includes recommendations for cancer biomarker providers in terms of product/service offerings geographic expansion, marketing strategies and target groups.
• Appendix- This section includes details on the NAICS codes covered, abbreviations and currencies codes used in this report.

Markets Covered:

• 1) By Biomarkers Type: Protein Biomarkers; Genetic Biomarkers; Other Cancer Biomarkers
• 2) By Profiling Technologies: Omics Technologies; Imaging Technologies; Immunoassay Bioinformatics; Cytogenetics
• 3) By Application: Diagnostics; Research and Development; Prognostics; Risk Assessment; Other Applications
• 4) By Cancer Type: Cervical Cancer; Breast Cancer; Lung Cancer; Brain and Central Nervous System Cancer; Kidney Cancer; Colorectal Cancer; Prostate Cancer; Ovarian Cancer; Stomach Cancer; Other Cancers
• Companies Mentioned: Roche Diagnostics; Novartis AG; Illumina; Hologic Inc.; Thermo Fisher Scientific
• Countries: China; Australia; India; Indonesia; Japan; South Korea; USA; Canada; Brazil; France; Germany; Italy; Spain; UK; Russia
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time-series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets; GDP proportions; expenditure per capita; cancer biomarker indicators comparison.
• Data segmentations: country and regional historic and forecast data; market share of competitors; market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.

Table of Contents

1 Executive Summary

• 1.1 Cancer Biomarker - Market Attractiveness And Macro economic Landscape

2 Table Of Contents

3 List Of Tables

4 List Of Figures

5 Report Structure

6 Market Characteristics

• 6.1 General Market Definition
• 6.2 Summary
• 6.3 Cancer Biomarker Market Definition And Segmentation
• 6.4 Market Segmentation By Biomarkers Type
  • 6.4.1 Protein Biomarkers
  • 6.4.2 Genetic Biomarkers
  • 6.4.3 Other Cancer Biomarkers
• 6.5 Market Segmentation By Profiling Technologies
  • 6.5.1 Omics Technologies
  • 6.5.2 Imaging Technologies
  • 6.5.3 Immunoassays
  • 6.5.4 Bioinformatics
  • 6.5.5 Cytogenetics
• 6.6 Market Segmentation By Cancer Type
  • 6.6.1 Cervical Cancer
  • 6.6.2 Breast Cancer
  • 6.6.3 Lung Cancer
  • 6.6.4 Colorectal Cancer
  • 6.6.5 Prostate Cancer
  • 6.6.6 Brain And Central Nervous System Cancer
  • 6.6.7 Kidney Cancer
  • 6.6.8 Ovarian Cancer
  • 6.6.9 Stomach Cancer
  • 6.6.10 Other Cancer Types
• 6.7 Market Segmentation By Application
  • 6.7.1 Diagnostics
  • 6.7.2 Research And Development
  • 6.7.3 Prognostics
  • 6.7.4 Risk Assessment
  • 6.7.5 Other Applications

7 Major Market Trends

• 7.1 Focus On AI Solution For Advancing Cancer Diagnostics And Cancer Drugs
• 7.2 Strategic Partnerships And Collaborations To Strengthen Market Position
• 7.3 Establishment Of Centre Of Excellence To Develop Biomarkers For Early Detection Of Cancer
• 7.4 Developments In Blood-Borne Circulating Biomarkers For Cancer Detection
• 7.5 Focus On Development Of Radioligand Therapy For Cancer Biomarker

8 Cancer Biomarker Market - Macro Economic Scenario

• 8.1 COVID-19 Impact On The Cancer Biomarker Market
• 8.2 Impact Of The War In Ukraine On The Cancer Biomarker Market
• 8.3 Impact Of High Inflation On The Cancer Biomarker Market

9 Global Market Size and Growth

• 9.1 Market Size
• 9.2 Historic Market Growth, 2018 - 2023, Value ($ Million)
  • 9.2.1 Market Drivers 2018 - 2023
  • 9.2.2 Market Restraints 2018 - 2023
• 9.3 Forecast Market Growth, 2023 - 2028, 2033F Value ($ Million)
  • 9.3.1 Market Drivers 2023 - 2028
  • 9.3.2 Market Restraints 2023 - 2028

10 Global Cancer Biomarker Market Segmentation

• 10.1 Global Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 10.2 Global Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 10.3 Global Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 10.4 Global Cancer Biomarker Market, Segmentation By Cancer Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

11 Cancer Biomarker Market, Regional and Country Analysis

• 11.1 Global Cancer Biomarker Market, By Region, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 11.2 Global Cancer Biomarker Market, By Country, Historic and Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

12 Asia-Pacific Market

• 12.1 Summary
• 12.2 Market Overview
  • 12.2.1 Region Information
  • 12.2.2 Market Information
  • 12.2.3 Background Information
  • 12.2.4 Government Initiatives
  • 12.2.5 Regulations
  • 12.2.6 Regulatory Bodies
  • 12.2.7 Major Associations
  • 12.2.8 Taxes Levied
  • 12.2.9 Corporate Tax Structure
  • 12.2.10 Investments
  • 12.2.11 Major Companies
• 12.3 Asia-Pacific Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 12.4 Asia-Pacific Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 12.5 Asia-Pacific Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 12.6 Asia-Pacific Cancer Biomarker Market: Country Analysis
• 12.7 China Market
• 12.8 Summary
• 12.9 Market Overview
  • 12.9.1 Country Information
  • 12.9.2 Market Information
  • 12.9.3 Background Information
  • 12.9.4 Government Initiatives
  • 12.9.5 Regulations
  • 12.9.6 Regulatory Bodies
  • 12.9.7 Major Associations
  • 12.9.8 Taxes Levied
  • 12.9.9 Corporate Tax Structure
  • 12.9.10 Investments
  • 12.9.11 Major Companies
• 12.10 China Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 12.11 China Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 12.12 China Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 12.13 India Market
• 12.14 India Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 12.15 India Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 12.16 India Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 12.17 Japan Market
• 12.18 Japan Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 12.19 Japan Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 12.20 Japan Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 12.21 Australia Market
• 12.22 Australia Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 12.23 Australia Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 12.24 Australia Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 12.25 Indonesia Market
• 12.26 Indonesia Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 12.27 Indonesia Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 12.28 Indonesia Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 12.29 South Korea Market
• 12.30 South Korea Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 12.31 South Korea Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 12.32 South Korea Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

13 Western Europe Market

• 13.1 Summary
• 13.2 Market Overview
  • 13.2.1 Region Information
  • 13.2.2 Market Information
  • 13.2.3 Background Information
  • 13.2.4 Government Initiatives
  • 13.2.5 Regulations
  • 13.2.6 Regulatory Bodies
  • 13.2.7 Major Associations
  • 13.2.8 Taxes Levied
  • 13.2.9 Corporate Tax Structure
  • 13.2.10 Investments
  • 13.2.11 Major Companies
• 13.3 Western Europe Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 13.4 Western Europe Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 13.5 Western Europe Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 13.6 Western Europe Cancer Biomarker Market: Country Analysis
• 13.7 UK Market
• 13.8 UK Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 13.9 UK Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 13.10 UK Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 13.11 Germany Market
• 13.12 Germany Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 13.13 Germany Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 13.14 Germany Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 13.15 France Market
• 13.16 France Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 13.17 France Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 13.18 France Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 13.19 Italy Market
• 13.20 Italy Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 13.21 Italy Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 13.22 Italy Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 13.23 Spain Market
• 13.24 Spain Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 13.25 Spain Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 13.26 Spain Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

14 Eastern Europe Market

• 14.1 Summary
• 14.2 Market Overview
  • 14.2.1 Region Information
  • 14.2.2 Market Information
  • 14.2.3 Background Information
  • 14.2.4 Government Initiatives
  • 14.2.5 Regulations
  • 14.2.6 Regulatory Bodies
  • 14.2.7 Major Associations
  • 14.2.8 Taxes Levied
  • 14.2.9 Corporate Tax Structure
  • 14.2.10 Investments
  • 14.2.11 Major Companies
• 14.3 Eastern Europe Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 14.4 Eastern Europe Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 14.5 Eastern Europe Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 14.6 Eastern Europe Cancer Biomarker Market: Country Analysis
• 14.7 Russia Market
• 14.8 Russia Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 14.9 Russia Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 14.10 Russia Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

15 North America Market

• 15.1 Summary
• 15.2 Market Overview
  • 15.2.1 Region Information
  • 15.2.2 Market Information
  • 15.2.3 Background Information
  • 15.2.4 Government Initiatives
  • 15.2.5 Regulations
  • 15.2.6 Regulatory Bodies
  • 15.2.7 Major Associations
  • 15.2.8 Taxes Levied
  • 15.2.9 Corporate Tax Structure
  • 15.2.10 Investments
  • 15.2.11 Major Companies
• 15.3 North America Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 15.4 North America Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 15.5 North America Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 15.6 North America Cancer Biomarker Market: Country Analysis
• 15.7 USA Market
• 15.8 Summary
• 15.9 Market Overview
  • 15.9.1 Country Information
  • 15.9.2 Market Information
  • 15.9.3 Background Information
  • 15.9.4 Government Initiatives
  • 15.9.5 Regulations
  • 15.9.6 Regulatory Bodies
  • 15.9.7 Major Associations
  • 15.9.8 Taxes Levied
  • 15.9.9 Corporate Tax Structure
  • 15.9.10 Investments
  • 15.9.11 Major Companies
• 15.10 USA Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 15.11 USA Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 15.12 USA Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 15.13 Canada Market
• 15.14 Canada Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 15.15 Canada Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 15.16 Canada Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

16 South America Market

• 16.1 Summary
• 16.2 Market Overview
  • 16.2.1 Region Information
  • 16.2.2 Market Information
  • 16.2.3 Background Information
  • 16.2.4 Government Initiatives
  • 16.2.5 Regulations
  • 16.2.6 Regulatory Bodies
  • 16.2.7 Major Associations
  • 16.2.8 Taxes Levied
  • 16.2.9 Corporate Tax Structure
  • 16.2.10 Investments
  • 16.2.11 Major Companies
• 16.3 South America Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 16.4 South America Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 16.5 South America Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 16.6 South America Cancer Biomarker Market: Country Analysis
• 16.7 Brazil Market
• 16.8 Brazil Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 16.9 Brazil Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 16.10 Brazil Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

17 Middle East Market

• 17.1 Summary
• 17.2 Market Overview
  • 17.2.1 Region Information
  • 17.2.2 Market Information
  • 17.2.3 Background Information
  • 17.2.4 Government Initiatives
  • 17.2.5 Regulations
  • 17.2.6 Regulatory Bodies
  • 17.2.7 Major Associations
  • 17.2.8 Taxes Levied
  • 17.2.9 Corporate Tax Structure
  • 17.2.10 Investments
  • 17.2.11 Major Companies
• 17.3 Middle East Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 17.4 Middle East Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 17.5 Middle East Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

18 Africa Market

• 18.1 Summary
• 18.2 Market Overview
  • 18.2.1 Region Information
  • 18.2.2 Market Information
  • 18.2.3 Background Information
  • 18.2.4 Government Initiatives
  • 18.2.5 Regulations
  • 18.2.6 Regulatory Bodies
  • 18.2.7 Major Associations
  • 18.2.8 Taxes Levied
  • 18.2.9 Corporate Tax Structure
  • 18.2.10 Investments
  • 18.2.11 Major Companies
• 18.3 Africa Cancer Biomarker Market, Segmentation By Biomarkers Type, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 18.4 Africa Cancer Biomarker Market, Segmentation By Profiling Technologies, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)
• 18.5 Africa Cancer Biomarker Market, Segmentation By Application, Historic And Forecast, 2018 - 2023, 2028F, 2033F, Value ($ Million)

19 Competitive Landscape and Company Profiles

• 19.1 Company Profiles
• 19.2 Roche Diagnostics
  • 19.2.1 Company Overview
  • 19.2.2 Products And Services
  • 19.2.3 Business Strategy
  • 19.2.4 Financial Overview
• 19.3 Novartis AG
  • 19.3.1 Company Overview
  • 19.3.2 Products And Services
  • 19.3.3 Business Strategy
  • 19.3.4 Financial Performance
• 19.4 Illumina Inc.
  • 19.4.1 Company Overview
  • 19.4.2 Products And Services
  • 19.4.3 Business Strategy
  • 19.4.4 Financial Overview
• 19.5 Hologic Inc
  • 19.5.1 Company Overview
  • 19.5.2 Products And Services
  • 19.5.3 Business Strategy
  • 19.5.4 Financial Overview
• 19.6 Thermo Fisher Scientific Inc.
  • 19.6.1 Company Overview
  • 19.6.2 Products And Services
  • 19.6.3 Business Strategy
  • 19.6.4 Financial performance

20 Competitive Benchmarking

21 Competitive Dashboard

22 Key Mergers And Acquisitions

• 22.1 Novartis Acquired MorphoSys
• 22.2 Bristol Myers Squibb Acquired Mirati Therapeutics
• 22.3 Agilent Acquired Avida Biomed
• 22.4 Quest Diagnostics Acquired Haystack Oncology
• 22.5 Prenetics Global Acquired ACT Genomics
• 22.6 Biocare Medical Acquired Empire Genomics
• 22.7 Agilent Acquired Resolution Bioscience
• 22.8 Hologic Acquired Biotheranostics

23 Opportunities And Strategies

• 23.1 Global Cancer Biomarker Market In 2028 - Countries Offering Most New Opportunities
• 23.2 Global Cancer Biomarker Market In 2028 - Segments Offering Most New Opportunities
• 23.3 Global Cancer Biomarker Market In 2028 - Growth Strategies
  • 23.3.1 Market Trend Based Strategies
  • 23.3.2 Competitor Strategies

24 Cancer Biomarker Market, Conclusions And Recommendations

• 24.1 Conclusions
• 24.2 Recommendations
  • 24.2.1 Product
  • 24.2.2 Place
  • 24.2.3 Price
  • 24.2.4 Promotion
  • 24.2.5 People

25 Appendix

• 25.1 Geographies Covered
• 25.2 Market Data Sources
• 25.3 Research Methodology
• 25.4 Currencies
• 25.5 The Business Research Company
• 25.6 Copyright and Disclaimer